Josh Richardson

Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA.

Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland.

Neurana Pharmaceuticals, Inc. engages in a biotechnology industry. It focused on the development of drugs to treat neuromuscular disorders. The company was founded in 2013 and is headquartered in San Diego, CA.

KaNDy Therapeutics Ltd. engages in the provision of a treatment of chronic debilitating female sex-hormone related conditions. Its product is NT-814 a non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms. The company was founded by Dr. Mike Trower and Mary Kerr in 2017 and is headquartered in Stevenage, the United Kingdom.

Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation.

Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles.